These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33098720)

  • 1. Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies.
    Ständer S; Schmidt E; Zillikens D; Thaçi D; Ludwig RJ; Kridin K
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):981-987. PubMed ID: 33098720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgE anti-BP180 NC16A autoantibody in both serum and blister fluid samples does not correlate with disease activity of bullous pemphigoid.
    Sun C; Qian H; Liang G; Xiang R; Zhao C; Li Z; Suo L; Jing K; Wang Y; Zhang H; Li X; Feng S
    Eur J Dermatol; 2023 Dec; 33(6):595-603. PubMed ID: 38465539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results.
    Kamata A; Kurihara Y; Funakoshi T; Takahashi H; Kuroda K; Hachiya T; Amagai M; Yamagami J
    Br J Dermatol; 2020 May; 182(5):1221-1227. PubMed ID: 31330562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
    Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
    Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
    Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
    JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid.
    Duretz C; Antonicelli F; Muller C; Antonicelli N; Plee J; Viguier M; Bernard P
    JAMA Dermatol; 2019 Feb; 155(2):216-220. PubMed ID: 30484821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with anti-BP230 seropositivity.
    Ständer S; Hammers CM; Vorobyev A; Schmidt E; Hundt JE; Sadik CD; Lange T; Zillikens D; Ludwig RJ; Kridin K
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2067-2073. PubMed ID: 33896070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
    Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
    Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid.
    Ständer S; Hammers CM; Vorobyev A; Schmidt E; Zillikens D; Ghorbanalipoor S; Bieber K; Ludwig RJ; Kridin K
    J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1702-1711. PubMed ID: 33896060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia.
    Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T
    J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid.
    Kamata M; Asano Y; Shida R; Maeda N; Yoshizaki A; Miyagaki T; Kawashima T; Tada Y; Sato S
    J Dermatol; 2019 Jun; 46(6):e216-e217. PubMed ID: 30628103
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
    Schmidt E; Obe K; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Feb; 136(2):174-8. PubMed ID: 10677092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.
    Holtsche MM; Goletz S; van Beek N; Zillikens D; Benoit S; Harman K; Walton S; English J; Sticherling M; Chapman A; Levell NJ; Groves R; Williams HC; König IR; Schmidt E;
    Br J Dermatol; 2018 Oct; 179(4):918-924. PubMed ID: 29607480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients.
    Lamberts A; Kotnik N; Diercks GFH; Meijer JM; Di Zenzo G; Pas HH; Jonkman MF; Gibbs BF; Raap U; Horváth B
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):973-980. PubMed ID: 33058320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-36 cytokines are overexpressed in the skin and sera of patients with bullous pemphigoid.
    Maglie R; Mercurio L; Morelli M; Madonna S; Salemme A; Baffa ME; Quintarelli L; Di Zenzo GM; Antiga E; Albanesi C
    Exp Dermatol; 2023 Jun; 32(6):915-921. PubMed ID: 36940975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
    Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
    J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.
    Masmoudi W; Vaillant M; Vassileva S; Patsatsi A; Quereux G; Moltrasio C; Abasq C; Prost-Squarcioni C; Kottler D; Kiritsi D; Litrowski N; Plantin P; Friedrichsen L; Zebrowska A; Duvert-Lehembre S; Hofmann S; Ferranti V; Jouen F; Joly P; Hebert V;
    Br J Dermatol; 2021 Jun; 184(6):1106-1112. PubMed ID: 33067805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.